Literature DB >> 3476202

Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.

E Madon, G Grazia, B De Bernardi, A Comelli, M Carli, L Sainati, G Paolucci, R Canino, R Colella, S Bagnulo.   

Abstract

A total of 17 pediatric patients with pretreated acute lymphoblastic leukemia were included in a phase II study of idarubicin. Four of 16 complete remissions were obtained, confirming the activity of the drug in this indication. Toxicity was acceptable, though caution is needed in patients who have already received high cumulative doses of anthracyclines.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3476202

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  3 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells.

Authors:  M Limonta; A Biondi; G Giudici; G Specchia; C Catapano; G Masera; T Barbui; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.